HC Wainwright & Co. Maintains Buy on Mainz Biomed, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen maintains a Buy rating on Mainz Biomed (NASDAQ:MYNZ) and raises the price target from $7 to $9.
September 22, 2023 | 4:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The Buy rating maintained by HC Wainwright & Co. and the raised price target could positively impact Mainz Biomed's stock in the short term.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, the Buy rating maintained by HC Wainwright & Co. and the raised price target from $7 to $9 indicate a positive outlook for Mainz Biomed, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100